Dynavax Technologies Corporation (NASDAQ: DVAX) 28.1% HIGHER; announced today that its GMP manufacturing facility in Dusseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV, the Company's investigational adult hepatitis B vaccine.
The approval comes as a result of an upgrade expanding production capacity. With an updated European Union GMP manufacturing license in place, Dynavax can meet the initial commercial production demands for the anticipated launch of HEPLISAV.
First BanCorp (NYSE:...
Unusual 11 Mid-Day Movers 07/08: FBP, BYFC, SNBC,...
First BanCorp (NYSE: FBP) 78.3% HIGHER; announced today that it has signed an agreement with the United States Department of the Treasury pursuant to which it will issue a new series of...
Unusual 11 Mid-Day Movers 3/16: ICGN, XFN, BTIM,...
Icagen, Inc. (Nasdaq: ICGN) 39.6% HIGHER; today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium...
Epson S041636 8.5inx11in Velvet Fine Art Paper...
Epson has earned a strong reputation for first-class printers, which offer an outstanding combination of quality, reliability and value for money. However, unless these products are...
Brother PT-1280 P-touch Electronic Labeling System
The PT-1280 is an affordable, feature-packed home & office labeler that can print laminated labels up to 1/2 inch wide. This unit features an easy-view 15 character display and can print up...
Post new comment